|
CA2537029A1
|
|
Micellar systems useful for delivery of lipophilic or hydrophobic compounds
|
|
WO2005046663A1
|
|
Compositions of quaternary ammonium containing bioavailability enhancers
|
|
WO2005046684A1
|
|
Once daily dosage forms of trospium
|
|
EP1606395A2
|
|
Accelerated culture system for intestinal epithelial cell monolayers
|
|
CA2514878A1
|
|
Drug formulation and delivery using crystalline methylated cyclodextrins
|
|
CA2490157A1
|
|
Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
|
|
US6772801B1
|
|
Fluidization of particles for encapsulation in oral dosage pharmaceutical products
|
|
US2004059002A1
|
|
Sustained release delivery of amphetamine salts
|
|
AU2002364212A1
|
|
Oral capsule formulation with increased physical stability
|
|
EP1539117A1
|
|
Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
|
|
AU2002364912A1
|
|
Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
|
|
WO02087621A1
|
|
Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
|
|
WO02060437A1
|
|
Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
|
|
US6811794B2
|
|
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
|
US6838093B2
|
|
System for osmotic delivery of pharmaceutically active agents
|
|
US6287599B1
|
|
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
|
AU6649200A
|
|
Soluble form osmotic dose delivery system
|
|
US6361796B1
|
|
Soluble form osmotic dose delivery system
|
|
US6384020B1
|
|
Rapid immediate release oral dosage form
|
|
US6793934B1
|
|
Solid oral dosage form
|
